Xilio Therapeutics Statistics

Total Valuation

XLO has a market cap or net worth of $39.12 million. The enterprise value is -$11.48 million.

Market Cap	39.12M
Enterprise Value	-11.48M

Important Dates

The last earnings date was Thursday, November 7, 2024, before market open.

Earnings Date	Nov 7, 2024
Ex-Dividend Date	n/a

Share Statistics

XLO has 43.95 million shares outstanding. The number of shares has increased by 61.00% in one year.

Current Share Class	43.95M
Shares Outstanding	43.95M
Shares Change (YoY)	+61.00%
Shares Change (QoQ)	+44.40%
Owned by Insiders (%)	16.38%
Owned by Institutions (%)	26.13%
Float	21.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	9.01
Forward PS	n/a
PB Ratio	1.97
P/TBV Ratio	1.97
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.67, with a Debt / Equity ratio of 0.40.

Current Ratio	1.67
Quick Ratio	1.61
Debt / Equity	0.40
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-320.73

Financial Efficiency

Return on equity (ROE) is -170.96% and return on invested capital (ROIC) is -83.23%.

Return on Equity (ROE)	-170.96%
Return on Assets (ROA)	-52.58%
Return on Capital (ROIC)	-83.23%
Revenue Per Employee	$63,288
Profits Per Employee	-$860,315
Employee Count	73
Asset Turnover	0.06
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -24.70% in the last 52 weeks. The beta is -0.20, so XLO's price volatility has been lower than the market average.

Beta (5Y)	-0.20
52-Week Price Change	-24.70%
50-Day Moving Average	0.91
200-Day Moving Average	0.93
Relative Strength Index (RSI)	46.12
Average Volume (20 Days)	461,726

Short Selling Information

The latest short interest is 396,085, so 0.90% of the outstanding shares have been sold short.

Short Interest	396,085
Short Previous Month	104,746
Short % of Shares Out	0.90%
Short % of Float	1.81%
Short Ratio (days to cover)	1.36

Income Statement

In the last 12 months, XLO had revenue of $4.62 million and -$62.80 million in losses. Loss per share was -$1.42.

Revenue	4.62M
Gross Profit	4.62M
Operating Income	-64.15M
Pretax Income	-65.53M
Net Income	-62.80M
EBITDA	-62.43M
EBIT	-64.15M
Loss Per Share	-$1.42

Full Income Statement

Balance Sheet

The company has $61.26 million in cash and $8.42 million in debt, giving a net cash position of $52.84 million or $1.20 per share.

Cash & Cash Equivalents	61.26M
Total Debt	8.42M
Net Cash	52.84M
Net Cash Per Share	$1.20
Equity (Book Value)	20.97M
Book Value Per Share	0.48
Working Capital	25.29M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$17.65 million and capital expenditures -$30,000, giving a free cash flow of -$17.68 million.

Operating Cash Flow	-17.65M
Capital Expenditures	-30,000
Free Cash Flow	-17.68M
FCF Per Share	-$0.40

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-1,388.44%
Pretax Margin	-1,359.37%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-736.78%

Dividends & Yields

XLO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-61.00%
Shareholder Yield	-61.00%
Earnings Yield	-151.82%
FCF Yield	-42.73%

Analyst Forecast

The average price target for XLO is $4.00, which is 349.44% higher than the current price. The consensus rating is "Buy".

Price Target	$4.00
Price Target Difference	349.44%
Analyst Consensus	Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-29.47%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

XLO has an Altman Z-Score of -8.94 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.94
Piotroski F-Score	1